RT Journal Article SR Electronic T1 First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension JF European Respiratory Journal JO Eur Respir J FD 188bet官网地址European Respiratory Society SP 785 OP 792 DO 10.1183/09031936.00039808 VO 33 IS 4 A1 Grimminger, F. A1 Weimann，G。A1Frey，R.A1 Voswinckel，R.A1 Thamm，M.A1Bölkow，D.A1 Weissmann，N.A1Mück，W.A1 Unger，S.A1 Wensing，S.A1 Wensing，G.A1 Schermuly，R.T.A1 Ghofrani，R.T.A1哈。YR 2009 UL //www.qdcxjkg.com/content/33/4/785.abstract AB肺动脉高压（pH）与血管舒张一氧化氮（NO）的产生受损有关。Riociguat（BAY 63-2521;拜耳医疗保健AG，德国Wuppertal）直接作用于可溶性鸟苷酸环化酶，刺激酶，并提高敏感性对低水平的敏感性。本研究评估了中度至重度pH（肺动脉高压，远端慢性血栓栓塞性pH或pH值轻度至中度间质肺疾病）患者的riociguat安全性，耐受性和功效。在四名pH患者中，通过增量给药来鉴定最佳耐受剂量。在10和5例pH患者中，单剂量给药（2.5 mg或1 mg）后，评估了药物动力学和药代动力学参数（2.5 mg或1 mg）。分析所有受试者（n = 19）的安全性和耐受性。riociguat的单剂量≤2.5mg时具有有利的安全性。它以剂量依赖性方式显着改善了pH患者的肺血液动力学参数和心脏指数，而不是吸入NO。 Although riociguat also had significant systemic effects and showed no pulmonary selectivity, mean systolic blood pressure remained >110 mmHg. The present report is the first to describe the use of riociguat in patients with pulmonary hypertension. The drug was well-tolerated and superior to nitric oxide in efficacy and duration. Riociguat, therefore, has potential as a novel therapy for pulmonary hypertension and warrants further investigation.